Absci Reports Interim Phase 1 ABS-201 Data With No Serious Adverse Events
Absci reported interim blinded Phase 1 data for ABS-201, an investigational antibody for androgenetic alopecia, showing study drug appeared well tolerated across 32 participants in four single ascending dose cohorts as of a June 8, 2026 data cutoff. The estimated half-life of at least 65 days is preliminary and supports a possible dosing schedule of two or three injections over six months, pending further follow-up. The filing contains no financial results or guidance, and the company expects interim proof-of-concept data in the second half of 2026.
Key points
- Interim data covers 32 healthy adult participants across four single ascending dose cohorts, with a June 8, 2026 data cutoff
- No serious adverse events reported as of the cutoff; treatment-related adverse events were reported in 5 participants and all were mild
- Estimated half-life for ABS-201 is at least 65 days, pending confirmation through continued follow-up
- Interim proof-of-concept data expected in the second half of 2026; full proof-of-concept data expected in early 2027
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 24, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.